Grb7, a Critical Mediator of EGFR/ErbB Signaling, in Cancer Development and as a Potential Therapeutic Target
Open accessThe DOI matches its Crossref record; 82 of the 86 references it cites were found in a registry or an index.
Abstract
The partner of activated epidermal growth factor receptor (EGFR), growth factor receptor bound protein-7 (Grb7), a functionally multidomain adaptor protein, has been demonstrated to be a pivotal regulator for varied physiological and pathological processes by interacting with phospho-tyrosine-related signaling molecules to affect the transmission through a number of signaling pathways. In particular, critical roles of Grb7 in erythroblastic leukemia viral oncogene homolog (ERBB) family-mediated cancer development and malignancy have been intensively evaluated. The overexpression of Grb7 or the coamplification/cooverexpression of Grb7 and members of the ERBB family play essential roles in advanced human cancers and are associated with decreased survival and recurrence of cancers, emphasizing Grb7′s value as a prognostic marker and a therapeutic target. Peptide inhibitors of Grb7 are being tested in preclinical trials for their possible therapeutic effects. Here, we review the molecular, functional, and clinical aspects of Grb7 in ERBB family-mediated cancer development and malignancy with the aim to reveal alternative and effective therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GRB7 inhibition, either alone, in combination chemotherapy [39, 40], or in combination targeted therapy improves the efficiency of antitumor therapy.”
From Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer (2022) · cites this paper as [39]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Perez, E. A., Olson, J. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510764 · Cited by 1,388
Rexer, B. N., & Arteaga, C. L. (2012) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v17.i1.20 · Cited by 370
Lee, H., Volonté, D., Galbiati, F., Iyengar, P., Lublin, D. M., Bregman, D. B., Wilson, M. T., Campos‐González, R., Bouzahzah, B., Pestell, R. G., et al. (2000) · Molecular Endocrinology · doi:10.1210/me.14.11.1750 · Cited by 327
Pleckstrin homology domains and the cytoskeleton
Lemmon, M. A., Ferguson, K. M., & Abrams, C. S. (2002) · FEBS Letters · doi:10.1016/s0014-5793(01)03243-4 · Cited by 262
Stein, D., Wu, J., Fuqua, S. A., Roonprapunt, C., Yajnik, V., D'Eustachio, P., Moskow, J. J., Buchberg, A. M., Osborne, C. K., & Margolis, B. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06386.x · Cited by 249
Emerging Roles of Focal Adhesion Kinase in Cancer
Tai, Y.-L., Chen, L.-C., & Shen, T.-L. (2015) · BioMed Research International · doi:10.1155/2015/690690 · Cited by 226
Self-citationAssociation of Focal Adhesion Kinase with Grb7 and Its Role in Cell Migration
Han, D. C., & Guan, J.-L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.24425 · Cited by 225
Kauraniemi, P., Barlund, M. T., Monni, O. M., & Kallioniemi, A. H. (2001) · PubMed · Cited by 214
Identification of Tek/Tie2 Binding Partners
Jones, N., Master, Z., Jones, J., Bouchard, D., Gunji, Y., Sasaki, H., Daly, R., Alitalo, K., & Dumont, D. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.43.30896 · Cited by 208
Research works printed but not linked: 1
- Tanaka, 2000, Grb7 signal transduction protein mediates metastatic progression of esophageal carcinoma, J. Cell Physiol., 183, 411, 10.1002/(sici)1097-4652(200006)183:3<411::aid-jcp14>3.0.co;2-z · DOI · Paper page
Cited by
circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer
Ling, Y., Liang, G., Lin, Q., Fang, X., Luo, Q., Cen, Y., Mehrpour, M., Hamaï, A., Liu, Z., Shi, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01476-7 · Cited by 101
Roles of microRNAs in Ovarian Cancer Tumorigenesis: Two Decades Later, What Have We Learned?
Alshamrani, A. A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01084 · Cited by 92
Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance
Singh, D. D., Parveen, A., & Yadav, D. K. (2021) · Biomedicines · doi:10.3390/biomedicines9111512 · Cited by 93
Yu, C., Luo, D., Yu, J., Zhang, M., Zheng, X., Xu, G., Wang, J., Wang, H., Xu, Y., Jiang, K., et al. (2022) · Oncogene · doi:10.1038/s41388-021-02077-w · Cited by 70
“GRB7 inhibition, either alone, in combination chemotherapy [39, 40], or in combination targeted therapy improves the efficiency of antitumor therapy.”
BackgroundPeptide-Based Strategies for Targeted Tumor Treatment and Imaging
Ayo, A., & Laakkonen, P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040481 · Cited by 71
Metadata
- Authors
- Chu, P.-Y., Tai, Y.-L., & Shen, T.-L.
- Affiliations
- National Taiwan University (TW)
- Corresponding author
- Shen, Tang-Long
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2019-05-10
- Volume
- 8
- Issue
- 5
- Pages
- 435
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC6562560
- OpenAlex
- W2944451168
- Cited by
- 84
- References
- 86
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 13 · 2023: 9 · 2022: 34 · 2021: 9 · 2020: 3 · 2019: 1
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Science and Technology, Taiwan (105‐2320‐B‐002‐058‐MY3, 106‐2911‐I‐002‐569)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- Grb7, epidermal growth factor receptor, ErbB family, adaptor proteins, carcinogenesis, prognostic factors, therapeutic target, peptide inhibitors, tumor recurrence, signaling pathways
- MeSH terms
- Humans, Neoplasms, Biomarkers, Tumor, Signal Transduction, GRB7 Adaptor Protein, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Grb7, a Critical Mediator of EGFR/ErbB Signaling, in Cancer Development and as a Potential Therapeutic Target. https://app.cochat.ai/papers/10.3390/cells8050435
- The paper
- Chu, P.-Y., Tai, Y.-L., & Shen, T.-L. (2019). Grb7, a Critical Mediator of EGFR/ErbB Signaling, in Cancer Development and as a Potential Therapeutic Target. Cells. https://doi.org/10.3390/cells8050435
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.